Bryan Due
Overview
Explore the profile of Bryan Due including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaplan J, Miller T, Baker M, Due B, Zhao E
Neurodegener Dis Manag
. 2021 Dec;
11(6):469-476.
PMID: 34860120
To determine whether clinicians evaluate American Academy of Neurology (AAN) quality metrics for patients with multiple sclerosis (MS) relapse and whether repository corticotropin injection (RCI) improves clinical and patient-reported outcomes...
2.
Poola N, Due B, Wright D, Brooks L, Zaman F
Clin Pharmacol Drug Dev
. 2021 Sep;
11(4):502-515.
PMID: 34528408
Repository corticotropin injection (RCI; Acthar Gel) is a naturally sourced complex mixture of adrenocorticotropic hormone (ACTH) analogs and other pituitary peptides. This phase 1, single-center, open-label, randomized parallel study directly...
3.
Kaplan J, Miller T, Baker M, Due B, Zhao E
Front Neurol
. 2021 Jan;
11:598496.
PMID: 33414758
Effective relapse treatment is critical for minimizing disability in patients with multiple sclerosis (MS). Repository corticotropin injection (RCI; Acthar® Gel) has demonstrated efficacy for the treatment of MS exacerbations. However,...
4.
Wang X, Pham L, Poola N, Brooks L, Due B
Clin Pharmacol Drug Dev
. 2020 Dec;
10(7):777-788.
PMID: 33369276
The pharmacokinetics (PK) and pharmacodynamics (PD) of clinically relevant doses of repository corticotropin injection (Acthar Gel) and synthetic ACTH depot have not been fully characterized. We compared the steroidogenic exposure...